Table 3. Comparative analysis of RL patients at MCC between 2010–2017 and their chronological peers with RL from the NCDB (by intention to treat) in the unmatched and matched datasets.
| Variables | Unmatched dataset | Matched dataset 1:3 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| MCC RL (N=667) | NCDB RL (N=15,816) | SD | P | MCC RL (N=493) | NCDB RL (N=1,479) | SD | P | ||
| Age, years | 68.62±9.22 | 67.80±9.54 | 0.017 | 0.007* | 68.42±9.23 | 68.22±9.71 | 0.004 | 0.702 | |
| Sex | 0.016 | 0.046* | 0.015 | 0.506 | |||||
| Males | 269 (40.3) | 6,999 (44.3) | 189 (38.3) | 592 (40.0) | |||||
| Females | 398 (59.7) | 8,817 (55.7) | 304 (61.7) | 887 (60.0) | |||||
| Race/ethnicity | 0.069 | <0.001* | 0.027 | 0.829 | |||||
| White | 631 (94.6) | 12,885 (81.5) | 463 (93.9) | 1,391 (94.1) | |||||
| Black | 15 (2.2) | 1,359 (8.6) | 14 (2.8) | 31 (2.1) | |||||
| Hispanic | 6 (0.9) | 879 (5.6) | 5 (1.0) | 20 (1.4) | |||||
| Asian | 10 (1.5) | 343 (2.2) | 8 (1.6) | 29 (2.0) | |||||
| Other | 5 (0.7) | 350 (2.2) | 3 (0.6) | 8 (0.5) | |||||
| Charlson score | 0.031 | <0.001* | 0.022 | 0.813 | |||||
| 0 | 348 (52.2) | 8,278 (52.3) | 255 (51.7) | 775 (52.4) | |||||
| 1 | 188 (28.2) | 5,056 (32.0) | 143 (29.0) | 409 (27.7) | |||||
| 2 | 80 (12.0) | 1,760 (11.1) | 57 (11.6) | 190 (12.8) | |||||
| 3+ | 51 (7.6) | 722 (4.6) | 38 (7.7) | 105 (7.1) | |||||
| Histology | 0.073 | <0.001* | 0.013 | 0.958 | |||||
| Adenocarcinoma | 456 (68.4) | 9,088 (57.5) | 331 (67.1) | 1,011 (68.4) | |||||
| SCC | 124 (18.6) | 3,575 (22.6) | 92 (18.7) | 267 (18.1) | |||||
| Neuroendocrine | 76 (11.4) | 1,245 (7.9) | 59 (12.0) | 167 (11.3) | |||||
| Other | 11 (1.6) | 1,908 (12.1) | 11 (2.2) | 34 (2.3) | |||||
| Grade | 0.063 | <0.001* | 0.02 | 0.845 | |||||
| Well difference | 198 (29.7) | 3,140 (19.9) | 159 (32.3) | 490 (33.1) | |||||
| Moderately difference | 286 (42.9) | 6,838 (43.2) | 205 (41.6) | 632 (42.7) | |||||
| Poorly difference | 168 (25.2) | 4,422 (28.0) | 117 (23.7) | 324 (21.9) | |||||
| Missing | 15 (2.2) | 1,416 (9.0) | 12 (2.4) | 33 (2.2) | |||||
| Side | 0.003 | 0.891 | |||||||
| Right | 430 (64.5) | 9,706 (61.4) | 321 (65.1) | 968 (65.4) | |||||
| Left | 233 (34.9) | 6,110 (38.6) | 172 (34.9) | 511 (34.6) | |||||
| Missing | 4 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||||
| Lobe | 0.035 | <0.001* | 0.01 | 0.907 | |||||
| Upper | 411 (61.6) | 8,914 (56.4) | 307 (62.3) | 897 (60.6) | |||||
| Middle | 58 (8.7) | 933 (5.9) | 45 (9.1) | 134 (9.1) | |||||
| Lower | 198 (29.7) | 5,969 (37.7) | 141 (28.6) | 448 (30.3) | |||||
| T stage | 0.364 | <0.001* | 0.069 | 0.1 | |||||
| Tis | 1 (0.1) | 65 (0.4) | 1 (0.2) | 3 (0.2) | |||||
| T1 | 363 (54.4) | 9,411 (59.5) | 360 (73.0) | 1,090 (73.7) | |||||
| T2 | 54 (8.1) | 3,849 (24.3) | 53 (10.8) | 204 (13.8) | |||||
| T3 | 44 (6.6) | 692 (4.4) | 44 (8.9) | 119 (8.0) | |||||
| T4 | 183 (27.4) | 142 (0.9) | 13 (2.6) | 43 (2.9) | |||||
| Tx | 22 (3.3) | 1,657 (10.5) | 22 (4.5) | 20 (1.4) | |||||
| N stage | 0.112 | <0.001* | 0.061 | 0.103 | |||||
| N0 | 512 (76.8) | 13,242 (83.7) | 411 (83.4) | 1,242 (84.0) | |||||
| N1 | 62 (9.3) | 801 (5.1) | 34 (6.9) | 110 (7.4) | |||||
| N2 | 93 (13.9) | 655 (4.1) | 48 (9.7) | 112 (7.6) | |||||
| Nx | 0 (0.0) | 1,118 (7.1) | 0 (0.0) | 15 (1.0) | |||||
| TNM stage | 0.14 | <0.001* | 0.059 | 0.195 | |||||
| Stage 0 | 0 (0.0) | 66 (0.4) | 0 (0.0) | 0 (0.0) | |||||
| Stage I | 410 (61.5) | 11,397 (72.1) | 312 (63.3) | 979 (66.2) | |||||
| Stage II | 131 (19.6) | 1,715 (10.8) | 101 (20.5) | 284 (19.2) | |||||
| Stage III | 123 (18.4) | 882 (5.6) | 78 (15.8) | 195 (13.2) | |||||
| Stage IV | 3 (0.4) | 5 (0.0) | 2 (0.4) | 0 (0.0) | |||||
| Unstageable | 0 (0.0) | 1,751 (11.1) | 0 (0.0) | 21 (1.4) | |||||
| Neoadjuvant systemic | 15 (2.2) | 476 (3.0) | 0.009 | 0.258 | 11 (2.2) | 29 (2.0) | 0.008 | 0.712 | |
| Neoadjuvant radiation | 3 (0.4) | 203 (1.3) | 0.015 | 0.058 | 3 (0.6) | 3 (0.2) | 0.032 | 0.157 | |
Data are shown as mean ± SD or number (percentage). *, statistically significant. RL, robotic lobectomy; MCC, Moffitt Cancer Center; NCDB, National Cancer Database; SD, standard difference; SCC, squamous cell carcinoma.